Nautilus Biotechnology, Inc. 8-K

What Happened

• On February 26, 2026, Nautilus Biotechnology, Inc. announced it reported financial results for the quarter and fiscal year ended December 31, 2025, and furnished the related press release as Exhibit 99.1 to a Form 8‑K. The filing was signed by Sujal Patel, Chief Executive Officer.

Key Details

• Filing date: February 26, 2026 (Form 8‑K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: Quarter and fiscal year ended December 31, 2025.
• Exhibit: Press release dated February 26, 2026 furnished as Exhibit 99.1.
• Signature: Report executed by Sujal Patel, CEO.

Why It Matters

• This Form 8‑K notifies investors that Nautilus has publicly released its latest quarterly and full‑year financial results; the press release (Exhibit 99.1) contains the details investors typically use to assess revenue, earnings, cash flow and year‑over‑year performance.
• Retail investors should review the attached press release and any related SEC filings (e.g., 10‑K or earnings presentation) for the specific figures, trends, and management commentary that affect valuation and near‑term outlook.